Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-11-01 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase (buyback) activities. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. It references previous announcements about the repurchase plan and reports but itself is an update on the repurchase progress. The document length is short (1547 characters) and it is not a full financial report or earnings release. It fits the category of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares.
2024-11-01 Chinese
安杰思2024年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '杭州安杰思医学科技股份有限公司 2024 年第三季度报告' which translates to 'Hangzhou Anjiesi Medical Technology Co., Ltd. 2024 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on non-recurring gains and losses. The report covers the third quarter of 2024 and includes unaudited financial statements, management assurances on accuracy, and detailed shareholder information. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length (13,980 characters) and content confirm it is the full report, not just an announcement or certification. Therefore, the appropriate classification is 'IR' for Interim / Quarterly Report. 9M 2024
2024-10-24 Chinese
安杰思第二届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board regarding the approval of the company's 2024 third quarter report. It states that the report was reviewed and found to be accurate and compliant, but the actual report is disclosed separately on the stock exchange website. The document itself is short (701 characters) and does not contain the financial data or substantive analysis of the quarterly report, only the approval and a reference to the report's publication elsewhere. According to the 'Menu vs Meal' rule, this is an announcement about the report, not the report itself. Therefore, the correct classification is Regulatory Filings (RNS).
2024-10-24 Chinese
杭州安杰思医学科技股份有限公司简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding by a significant shareholder (苏州元生私募基金管理合伙企业) in the listed company 杭州安杰思医学科技股份有限公司. The document includes detailed information about the shareholder, the nature of the shareholding change (a reduction in shares held), the legal basis for disclosure, and the specifics of the share transactions over a recent period. It references compliance with Chinese securities laws and disclosure standards specifically related to equity changes. There is no indication that this is an annual report, earnings release, or any other financial report. Instead, it is a formal notification of a change in major shareholding, consistent with the definition of "Major Shareholding Notification (MRQ)" which covers notifications of changes in significant share ownership levels crossing thresholds. The document length and content confirm it is the report itself, not just an announcement of a report publication or a certification. Therefore, the correct classification is MRQ.
2024-10-09 Chinese
安杰思关于持股5%以上股东减持股份至5%的权益变动提示公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder's reduction of their stake from just above 5% to exactly 5%, which means the shareholder is no longer a 5% or greater shareholder. It includes details about the shareholder, the reduction method, dates, and the impact on ownership percentages. The document references a previously disclosed share reduction plan and clarifies that this change does not affect control or governance. This type of announcement fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds such as 5%. The document is not a full financial report, earnings release, or management report, nor is it a regulatory filing or report publication announcement. Therefore, the correct classification is MRQ with high confidence.
2024-10-09 Chinese
安杰思关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. It references previous announcements about the share repurchase plan and reports on the progress as of a specific date. The document does not contain full financial statements or comprehensive financial analysis but focuses on the update of the share buyback activity. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2024-10-08 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.